UroGen Pharma Ltd. (URGN): Cost of Revenue
$12.45M
Year ended 2025-12-31
$17.28M
Trailing 12 months to 2026-06-30
+17.6%
3-year compound annual growth
+65.3%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $12.45M | +40.2% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $8.88M | -5.1% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $9.36M | +22.3% | 2025-03-10, From 2023-01-01 |
| 2022-12-31 | $7.65M | +48.4% | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | $5.16M | +411.1% | 2023-03-24, From 2021-01-01 |
| 2020-12-31 | $1.01M | n/a | 2022-03-21, From 2020-01-01 |
| No annual figure between 2018-12-31 and 2020-12-31. | |||
| 2018-12-31 | $1.80M | +200.5% | 2020-03-02, From 2018-01-01 |
| 2017-12-31 | $600.0K | n/m | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $28.0K | n/a | 2019-02-28, From 2016-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $12.45M | +40.2% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $5.42M | +39.4% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $29.70M | -5.1% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $88.57M | +2.5% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $42.79M | -7.2% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $5.80M | -2.5% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $73.85M | +68.0% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $0 | -100.0% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $37.21M | +138.5% |
Compare URGN, GYRE, SIGA, LFCR side by side · Screen every company in Pharmaceutical Preparations ↗